Summary
The purpose of this study is to learn about the effects of three study medicines
[maplirpacept (PF-07901801), tafasitamab, and lenalidomide] when given together for the
treatment of diffuse large B-cell lymphoma (DLBCL) that:
- is relapsed (has returned after last treatment) or
- is refractory (has not responded to last treatment)
DLBCL is a type of non-Hodgkin lymphoma (NHL). NHL is a cancer of the lymphatic system.
It develops when the body makes abnormal lymphocytes. These lymphocytes are a type of
white blood cell that normally help to fight infections.
This study is seeking participants who are unable or unwilling to undergo an autologous
stem cell transplantation (when doctors put healthy blood cells back into your body) or
CAR-T immune cell therapy.
Everyone in this study will receive three medicines: maplirpacept (PF-07901801),
tafasitamab and lenalidomide. Participants will receive maplirpacept (PF-07901801) and
tafasitamab at the study clinic by intravenous (IV) infusion (given directly into a vein)
and lenalidomide will be taken by mouth at home. Study interventions will be administered
in 28-day cycles. Maplirpacept (PF-07901801) will be given weekly for the first three
cycles and then every two weeks. Tafasitamab will administered on Days 1, 4, 8, 15 and 22
in cycle 1, weekly in cycles 2 and 3 and then every 2 weeks in cycle 4 and beyond.
Lenalidomide will be taken every day for Days 1 to 21 of each 28-day cycle for the first
12 cycles.
Participants can continue to take maplirpacept (PF-07901801) and tafasitamab until their
lymphoma is no longer responding. Lenalidomide is discontinued after 12 cycles.
Maplirpacept (PF-07901801) will be given at different doses to different participants.
Everyone taking part will receive approved doses of tafasitamab and lenalidomide. We will
compare the experiences of people receiving different doses of PF-07901801. This will
help us to determine what dose is safe and effective when combined with the other 2 study
medicines.